GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » AngioDynamics Inc (FRA:UG2) » Definitions » Cyclically Adjusted Revenue per Share

AngioDynamics (FRA:UG2) Cyclically Adjusted Revenue per Share : €8.85 (As of Feb. 2024)


View and export this data going back to 2013. Start your Free Trial

What is AngioDynamics Cyclically Adjusted Revenue per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

AngioDynamics's adjusted revenue per share for the three months ended in Feb. 2024 was €1.732. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is €8.85 for the trailing ten years ended in Feb. 2024.

During the past 12 months, AngioDynamics's average Cyclically Adjusted Revenue Growth Rate was -1.90% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 2.50% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 0.90% per year. During the past 10 years, the average Cyclically Adjusted Revenue Growth Rate was 1.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of AngioDynamics was 5.20% per year. The lowest was -0.70% per year. And the median was 1.95% per year.

As of today (2024-05-26), AngioDynamics's current stock price is €5.60. AngioDynamics's Cyclically Adjusted Revenue per Share for the quarter that ended in Feb. 2024 was €8.85. AngioDynamics's Cyclically Adjusted PS Ratio of today is 0.63.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of AngioDynamics was 3.26. The lowest was 0.55. And the median was 1.76.


AngioDynamics Cyclically Adjusted Revenue per Share Historical Data

The historical data trend for AngioDynamics's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AngioDynamics Cyclically Adjusted Revenue per Share Chart

AngioDynamics Annual Data
Trend May14 May15 May16 May17 May18 May19 May20 May21 May22 May23
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 8.52 8.07 7.60 9.16 9.06

AngioDynamics Quarterly Data
May19 Aug19 Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 9.29 9.06 8.99 8.81 8.85

Competitive Comparison of AngioDynamics's Cyclically Adjusted Revenue per Share

For the Medical Instruments & Supplies subindustry, AngioDynamics's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


AngioDynamics's Cyclically Adjusted PS Ratio Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, AngioDynamics's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where AngioDynamics's Cyclically Adjusted PS Ratio falls into.



AngioDynamics Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, AngioDynamics's adjusted Revenue per Share data for the three months ended in Feb. 2024 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Feb. 2024 (Change)*Current CPI (Feb. 2024)
=1.732/130.9299*130.9299
=1.732

Current CPI (Feb. 2024) = 130.9299.

AngioDynamics Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201405 1.921 100.373 2.506
201408 1.828 100.352 2.385
201411 2.046 99.635 2.689
201502 2.134 99.032 2.821
201505 2.247 100.333 2.932
201508 2.091 100.548 2.723
201511 2.303 100.135 3.011
201602 2.167 100.040 2.836
201605 2.269 101.355 2.931
201608 2.141 101.617 2.759
201611 2.222 101.829 2.857
201702 2.165 102.779 2.758
201705 0.174 103.256 0.221
201708 1.960 103.587 2.477
201711 1.976 104.072 2.486
201802 1.814 105.052 2.261
201805 0.129 106.148 0.159
201808 1.484 106.383 1.826
201811 1.642 106.338 2.022
201902 1.539 106.649 1.889
201905 1.692 108.048 2.050
201908 1.571 108.245 1.900
201911 1.668 108.519 2.012
202002 1.684 109.139 2.020
202005 1.405 108.175 1.701
202008 1.555 109.662 1.857
202011 1.606 109.793 1.915
202102 1.535 110.968 1.811
202105 1.641 113.576 1.892
202108 1.689 115.421 1.916
202111 1.756 117.269 1.961
202202 1.667 119.703 1.823
202205 2.102 123.323 2.232
202208 2.048 124.958 2.146
202211 2.122 125.607 2.212
202302 1.908 126.928 1.968
202305 2.115 128.314 2.158
202308 1.805 129.538 1.824
202311 1.817 129.548 1.836
202402 1.732 130.930 1.732

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.


AngioDynamics  (FRA:UG2) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

AngioDynamics's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=5.60/8.85
=0.63

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of AngioDynamics was 3.26. The lowest was 0.55. And the median was 1.76.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


AngioDynamics Cyclically Adjusted Revenue per Share Related Terms

Thank you for viewing the detailed overview of AngioDynamics's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


AngioDynamics (FRA:UG2) Business Description

Traded in Other Exchanges
Address
14 Plaza Drive, Latham, NY, USA, 12110
AngioDynamics Inc designs manufactures, and sells medical, surgical, and diagnostic devices used by professional healthcare providers for the treatment of peripheral vascular disease and for use in oncology and surgical settings. It generates maximum revenue from Endovascular Therapies. Geographically, the company derives a majority of its revenue from the United States.

AngioDynamics (FRA:UG2) Headlines

No Headlines